When THC attaches to the receptor, the effect is like an off switch to a light bulb, effectively turning "off" the pain. But ...

The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe acute pain in adults.

In 2004, a research group at Peking University First Hospital discovered a mutation in the gene coding for a sodium-channel ...

The drug offers a non-addictive alternative to opioids, marking 'an important public health milestone in acute pain ...

The Food and Drug Administration announced the approval of a new non-opioid pain medication this week, marking the first time ...

The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...

WASHINGTON — Federal officials on Thursday approved a new type of pain pill designed to eliminate the risks of addiction and ...

Anti-CGRP antibodies vs onabotulinumtoxinA is not associated with increased cardiovascular disease risk in older patients ...

SAN DIEGO, CA and SOUTH SAN FRANCISCO, CA / ACCESS Newswire / January 21, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata") and Revance ...

Cervical dystonia (≥5%): headache (9%), injection site pain (8%), injection ... in the U.S. Revance has also partnered with Viatris Inc. to develop a biosimilar to onabotulinumtoxinA for injection and ...

Revance's portfolio includes Daxxify® (DaxibotulinumtoxinA-lanm) for injection and the RHA® Collection of dermal fillers in the U.S. Revance has also partnered with Viatris Inc. to ...

Migraine is a neurological condition. The hallmark symptom of migraine is an intense headache, often described as pounding or throbbing. It’s usually accompanied by other symptoms like nausea ...